Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.84 (market cap $6.04B), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.38 (market cap $72.20B). The key difference: Vanguard Intermediate Term Corporate Bond ETF is far larger — about 12× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Vanguard Intermediate Term Corporate Bond ETF for 61 Days on average.
| IOVA | VCIT | |
|---|---|---|
Market Cap | $6.04B | $72.20B |
Volume | 14,805,993 | 7,532,796 |
Sector | Health | Fixed Income |
52-Week High | $14.82 | $84.82 |
52-Week Low | $1.81 | $77.98 |
Typical Hold Time | 0 Days | 61 Days |
Enterprise Value | $5.97B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VCIT trades at $78.345 with minimal daily movement (+0.1%). Technical indicators show a bearish trend with moving averages signaling caution, though oscillators are neutral. The ETF maintains consistent dividend distributions of $0.34 per share. Recent institutional interest includes Engineers Gate Manager LP's $1.27 million investment and HB Wealth Management's 242.9% position increase.
VCIT offers a compelling 4.8% yield with low 0.03% expense ratio, positioning it favorably against peers. However, bearish technical signals and interest rate sensitivity present near-term risks. The fund's intermediate-term corporate bond focus provides balanced risk-return profile for income-seeking investors in current economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
